GlassScriptPhysician profile
Stephanie Coyle
NPI 1265017784
$890.05
in general payments reported to CMS, 2019-2025
22 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $80.52 · 2022: $88.51 · 2023: $188 · 2024: $352 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $145.56 | 2022-2025 | Wegovy, Ozempic, Saxenda |
| Pfizer INC. | $110.22 | 2023-2025 | |
| Abbvie INC. | $107.13 | 2021-2024 | |
| Lilly USA, LLC | $63.03 | 2023-2025 | Mounjaro, Zepbound |
| Stryker Corporation | $61.12 | 2024 | Knotilus Anchor, 3.5mm |
| Integra Lifesciences Corporation | $44.48 | 2023 | Durasorb Monofilament Mesh |
| Genzyme Corporation | $42.28 | 2021-2024 | |
| Alkermes, INC. | $35.27 | 2022-2023 | Vivitrol |
| Inspire Medical Systems, INC. | $34.92 | 2025 | Inspire |
| Axsome Therapeutics, INC. | $26.37 | 2024 | Sunosi |
| Supernus Pharmaceuticals, INC. | $25.33 | 2024 | Qelbree |
| Mayne Pharma Commercial LLC | $23.05 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $21.65 | 2024 | Farxiga |
| Lundbeck LLC | $20.89 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $18.84 | 2024 | Voquezna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.04 | 2023 | Xifaxan |
| Exact Sciences Corporation | $17.16 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $16.19 | 2022 | |
| Amarin Pharma, INC. | $16.12 | 2021 | |
| Currax Pharmaceuticals LLC | $15.37 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.02 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Coyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.